Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC

Inclusion Criteria: * ECOG PS 0-3; * Pathologically confirmed adenocarcinoma in stomach or esophagogastric junction; * Bone marrow metastasis confirmed by aspiration, biopsy or PET/CT scan; * overt DIC according to the International Society on Thrombosis and Haemostasis (ISTH) criteria; * Treatment-naive after the diagnosis of metastasis; * Platelet ≤ 50 \* 10E9/L; * ALT≤5×ULN, AST≤5×ULN, Bilirubin≤5×ULN, Creatinine≤3×ULN; * Written informed consent. Exclusion Criteria: * Concurrent aggressive malignancy; * Docetaxel containing perioperative treatment within 6 months; * Allergic to the study drugs; * Serious medical conditions, including severe heart disease, severe cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection,etc. * HIV positive; * MSI-H; * Her-2 gene overexpression; * Inadequate contraceptive measures.